ACXP Key Statistics, Chart & Performance
The current stock price of ACXP is 3.88 USD. In the past month the price decreased by -33.98%. In the past year, price decreased by -85%.
ACXP Latest News, Press Relases and Analysis
ACXP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.06 | 401.66B | ||
| AMGN | AMGEN INC | 15.77 | 185.65B | ||
| GILD | GILEAD SCIENCES INC | 15.38 | 156.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.8 | 110.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.43 | 83.14B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 891.59 | 59.60B | ||
| INSM | INSMED INC | N/A | 43.88B | ||
| NTRA | NATERA INC | N/A | 32.65B | ||
| BIIB | BIOGEN INC | 10.88 | 26.69B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.49 | 22.06B | ||
| INCY | INCYTE CORP | 16.32 | 20.47B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About ACXP
Company Profile
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. The company is headquartered in Staten Island, New York and currently employs 4 full-time employees. The company went IPO on 2021-06-25. The company develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.
Company Info
ACURX PHARMACEUTICALS INC
259 Liberty Avenue
Staten Island NEW YORK US
CEO: David P. Luci
Employees: 4
Phone: 19175331469
ACURX PHARMACEUTICALS INC / ACXP FAQ
What does ACURX PHARMACEUTICALS INC do?
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. The company is headquartered in Staten Island, New York and currently employs 4 full-time employees. The company went IPO on 2021-06-25. The company develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.
What is the stock price of ACURX PHARMACEUTICALS INC today?
The current stock price of ACXP is 3.88 USD. The price increased by 3.47% in the last trading session.
Does ACURX PHARMACEUTICALS INC pay dividends?
ACXP does not pay a dividend.
What is the ChartMill technical and fundamental rating of ACXP stock?
ACXP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for ACXP stock?
ACURX PHARMACEUTICALS INC (ACXP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.52).
Can you provide the number of employees for ACURX PHARMACEUTICALS INC?
ACURX PHARMACEUTICALS INC (ACXP) currently has 4 employees.
Can you provide the market cap for ACURX PHARMACEUTICALS INC?
ACURX PHARMACEUTICALS INC (ACXP) has a market capitalization of 6.13M USD. This makes ACXP a Nano Cap stock.
ACXP Technical Analysis
ACXP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ACXP. ACXP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ACXP Financial Highlights
Over the last trailing twelve months ACXP reported a non-GAAP Earnings per Share(EPS) of -8.52. The EPS increased by 7.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -162.38% | ||
| ROE | -280.37% | ||
| Debt/Equity | 0 |
ACXP Forecast & Estimates
9 analysts have analysed ACXP and the average price target is 62.93 USD. This implies a price increase of 1522.01% is expected in the next year compared to the current price of 3.88.